November 27-29 2018
Cambridge, MA, USA

 

Speakers

Expand/Collapse

Alexey Lugovsky
Chief Development Officer
Morphic Therapeutics

Alexey A. Lugovskoy, PhD is Chief Development Officer of Morphic Therapeutic Inc., responsible for product development strategy and operations. Previously Alex served as a Vice President of Therapeutics of Merrimack Pharmaceuticals, where his efforts were instrumental to the discovery of five oncology drug candidates and the development of antibody and antibody-drug conjugate discovery capabilities. In addition, he led the development for istiratumab from the design stage into the biomarker selected Phase 2 clinical trials.  Prior to joining Merrimack Alex served as Associate Director of Drug Discovery in Biogen. There, he co-discovered the inhibitors of three integrins and methods for the detection of the John Cunningham polyomavirus that is associated with increased risk of progressive multifocal leukoencephalopathy. Alex is an Assistant Editor of mAbs, a member of the editorial board of Research and Reports in Biochemistry and a member of the advisory council of RBV Capital. He is a co-author of over one hundred patents and publications. Alex has received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in biophysics from Harvard University, and a M.Sc. in molecular biophysics and B.Sc. in math and physics from Moscow Institute of Physics and Technology.

Day Two

Thursday, November 29, 2018

11.15 | Integrin Targets with Pharmacological Relevance in Inflammation & Fibrosis

09.00 | Panel Discussion: Fibrosis A Cause or a Consequence?

Andy Blanchard
Director External Discovery
GSK

Day Two

Thursday, November 29, 2018

10.30 | The Importance of Patient Stratification to Fibrosis Clinical Studies

Charles Theuer
Chief Executive Officer
Tracon Pharmaceuticals

Charles P. Theuer, M.D., Ph.D. – Director, President and Chief Executive Officer – Dr. Theuer has been CEO and President of TRACO, and a Director of TRACON Pharmaceuticals (NASDAQ: TCON) since 2006. Prior thereto, from October 2004 to July 2006, Dr. Theuer was Chief Medical Officer at TargeGen Inc., where he led the development of small molecule kinase inhibitors in oncology (including fedratinib, a jak2 inhibitor), ophthalmology and cardiovascular disease.  From October 2003 to October 2004, Dr. Theuer was the Director, Clinical Oncology at Pfizer, where he led the clinical development of Sutent® (sunitinib maleate) in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in January 2006 for treating advanced kidney cancer.  Prior thereto, Dr. Theuer held senior positions at IDEC Pharmaceuticals, from June 2002 to October 2003, and the National Cancer Institute developing other agents, including small molecules and monoclonal antibody therapies.  Dr. Theuer holds a B.S. degree from the Massachusetts Institute of Technology, an M.D. degree from the University of California, San Francisco and a Ph.D. degree from the University of California, Irvine.  He completed a residency in general surgery at Harbor-UCLA Medical Center and was Board Certified in general surgery in 1997.  Dr. Theuer held academic positions at the National Cancer Institute (NCI) and at the University of California, Irvine, where he was a member of the Division of Surgical Oncology.  His previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, as well as gastro-intestinal cancer epidemiology.

Day One

Wednesday, November 28, 2018

14.00 | Targeting Endoglin: Evolving an Oncology Therapy for the Treatment of Fibrosis

David Lagares
Director of the Matrix and Mechanobiology Program
Massachusetts General Hospital

Day Two

Thursday, November 29, 2018

09.00 | Panel Discussion: Fibrosis A Cause or a Consequence?

08.30 | Overview of Novel Anti-Fibrotic Therapies

Gerald Horan
Director Translational Science
Celgene

Day One

Wednesday, November 28, 2018

13.30 | Outlining Re-Direction Rationale of Existing Anti-Fibrotics to Treat Further Fibrosis Disorders

Guillermo Torre-Amione
Chief Medical Officer
Cardiol Therapeutics

Day Two

Thursday, November 29, 2018

09.30 | Anti-fibrotic Therapies for the Heart

Harold Shlevin
Chief Executive Officer
Galectin Therapeutics

Day Two

Thursday, November 29, 2018

14.00 | Physiological Control Systems Involving Galectins in Treatment of Diseases

Jeffrey Browning
Research Professor
Boston University

Workshop A

Tuesday, November 27, 2018

08.00 | Addressing the Complexities of Fibrosis Pathology in the Context of a Heterogeneous Pathology

Mark Tepper
President & Chief Scientific Officer
Corbus Pharmaceuticals

Mark A. Tepper, Ph.D., co-founded the Company in 2009. He has more than twenty years of leadership experience in pharmaceutical R&D and his past roles include leadership positions at Bristol Myers Squibb, Serono, CytRx, RXi Pharmaceuticals and NKT Therapeutics. Dr. Tepper has led teams in the discovery and development of a number of first-in-class drugs, including Guspermis, Taxol, Rebif, Orcenia and Gonal-F. During the last 10 years Dr. Tepper has focused his career on identifying unique early stage biotechnology assets, which fill a significant unmet medical need and forming companies to commercialize these assets. In this role, he has successfully founded and developed the commercialization strategy for 3 new biotech companies, raising over $45M in funding. Dr. Tepper received a Ph.D. in Biochemistry & Biophysics from Columbia University, College of Physicians & Surgeons, New York, and a B.A. in Chemistry with Highest Honors from Clark University, Worcester, Mass. He gained postdoctoral training at the University of Massachusetts Medical School, Worcester, MA in the laboratory of Professor Michael P. Czech.

Day One

Wednesday, November 28, 2018

16.00 | Achieving Meaningful Clinical Benefit Without Immunosuppression

Martin Phillips
Chief Executive Officer
Opsidio

Day Two

Thursday, November 29, 2018

15.00 | Stem Cell Factor: A Critical Activating Mechanism in Tissue Remodeling

Masha Poyurovsky
Vice President, Head of Molecular Signalling
Kadmon Pharmaceuticals

Dr. Poyurovsky serves as Vice President, Molecular Signaling at Kadmon. Dr. Poyurovsky’s focus is small molecule discovery, mechanism of action studies and nonclinical development. Dr. Poyurovsky also works closely with Kadmon’s Business Development team as a scientific liaison. Prior to joining Kadmon in 2011, Dr. Poyurovsky spent more than ten years studying cellular and molecular mechanisms of cancer in an academic setting. Dr. Poyurovsky received her B.S. in Biology from the University of Pittsburgh and her Ph.D. in Biochemistry from Columbia University. Dr. Poyurovsky continued her postgraduate work at Columbia, first as a postdoctoral fellow and then independently, as a staff scientist.

Day Two

Thursday, November 29, 2018

11.45 | Development of 3rd Generation Rho Kinase Inhibitors Targeting Fibrotic Diseases

Matthew Breyer
Distinguished Scientist, Cardiovascular & Metabolism
Janssen Pharmaceuticals

Day Two

Thursday, November 29, 2018

09.00 | Panel Discussion: Fibrosis A Cause or a Consequence?

Peter Blume-Jensen
Chief Executive Officer
Acrivon Therapeutics

Day Two

Thursday, November 29, 2018

09.00 | Panel Discussion: Fibrosis A Cause or a Consequence?

Peter Bunyard
Head of Immunology Biology
RedX Pharma

Dr. Peter Bunyard obtained his PhD in Immunology in 2002 from University College London and after post-doctoral research at Nottingham University has worked in auto-immune and fibrosis drug discovery. Peter’s career has progressed through a number of biotech and pharmaceutical companies including Celltech-UCB, GSK and Takeda. Currently Peter is head of fibrosis research at the UK biotech company Redx Pharma.

Day Two

Thursday, November 29, 2018

15.30 | Wnt Pathway Suppression & Fibrosis

Richard Marshall
Chief Medical Officer
Galecto Biotech

Day One

Wednesday, November 28, 2018

17.00 | Chair’s Closing Remarks

08.30 | Mapping the Future of Anti-Fibrotics: Why We’ve Failed & What Needs to be Done for Success

08.20 | Chair’s Opening Remarks

Day Two

Thursday, November 29, 2018

16.00 | Chair’s Closing Remarks

08.20 | Chair’s Opening Remarks

Ruogang Zhao
Assistant Professor of Biomedical Engineering
University of Buffalo

Day One

Wednesday, November 28, 2018

14.30 | Improving the Clinical Relevancy of Engineered Tissues for Disease Modelling & Drug Screening in Fibrosis

Sean Muthian
Executive Director - External Science Innovations
Allergan

Day One

Wednesday, November 28, 2018

09.00 | Session Details to be Confirmed

Sofia Mayans
Chief Executive Officer
Inficure Bio

Day One

Wednesday, November 28, 2018

11.30 | The N-IF Mouse - a New & Unique Fibrosis Model for Preclinical Efficacy Studies

Viktor Martyanov
Research Scientist
Geisel School of Medicine at Dartmouth Department of Molecular & Systems Biology

Day One

Wednesday, November 28, 2018

12.00 | Leveraging Pathways, Subsets & Networks to Better Analyze Clinical Trials: Lessons from Systemic Sclerosis

Wolfgang Jarolimek
Head of Drug Discovery
Pharmaxis

Wolfgang joined Pharmaxis in September 2010 as Manager in vitroPharmacology and was appointed Head Drug Discovery in August 2012.

He has more than 15 years’ experience in pharmaceutical drug discovery and has published more than 20 peer reviewed articles. From 2002 to 2010 Wolfgang was Director of Assay Development and Compound Profiling at the GlaxoSmithKline Center of Excellence in Drug Discovery in Verona, Italy. In addition to chairing early drug discovery efforts locally he also had global responsibilities for ion channel screening and implementing safety-related screening. From 1998 to 2002 he worked at the Neuroscience Center of Merck, Sharp and Dohme in Harlow, England, as Senior Research Scientist in the electrophysiology group. Wolfgang previously spent 8 years as post-doc at the Max-Plank Institute in Munich, Germany; Baylor College of Medicine, Houston, Texas; Rammelkamp Center, Cleveland Ohio; and University of Heidelberg, Germany.

Wolfgang holds a BSc in Pharmacy and a PhD from the University of Saarbrücken, Germany. In 1997 he became Assistant Professor in Physiology at the University of Heidelberg, Germany.

Day Two

Thursday, November 29, 2018

13.30 | Reducing Fibrosis by Inhibiting Lysyl Oxidases

John Liles
Senior Research Scientist
Gilead

Day One

Wednesday, November 28, 2018

16.30 | Therapeutic Potential of ASK1 Inhibition to Reduce Kidney Injury & Fibrosis

Jane Connor
Associate Director - MedImmune Respiratory Inflammation & Autoimmune Research
MedImmune

Day One

Wednesday, November 28, 2018

11.00 | Approaches to Identifying Novel Therapeutic Targets for Fibrosis: Lessons Learned & Future Directions

Komathi Stem
Founder & Chief Executive Officer
monARC Bionetworks

Day Two

Thursday, November 29, 2018

11.00 | Transforming IPF Clinical Trials Through Direct Patient Engagement

Maria Trojanowska
Professor, Medicine
Boston University

Workshop A

Tuesday, November 27, 2018

08.00 | Addressing the Complexities of Fibrosis Pathology in the Context of a Heterogeneous Pathology

Rana Herro
Junior Faqculty Instructor
La Jolla Institute for Allergy & Immunology

Workshop B

Tuesday, November 27, 2018

11.30 | Prognostics, Therapeutics & Theranostics in Fibrosis

Michael Underhill
Professor, Department of Cellular & Physiological Sciences
University of British Columbia

Workshop C

Tuesday, November 27, 2018

15.00 | Fibrosis as a Progenitor Disease

Fabio Rossi
Professor in Medical Genetics
University of British Columbia

Workshop C

Tuesday, November 27, 2018

15.00 | Fibrosis as a Progenitor Disease

Dario Lemos
Instructor in Medicine (Harvard Medical School) and Associate Bioengineer (Brigham & Women's Hospital)

Workshop C

Tuesday, November 27, 2018

15.00 | Fibrosis as a Progenitor Disease